Point72 Asia Singapore Pte. Ltd. Takes Position in Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM)

Point72 Asia Singapore Pte. Ltd. purchased a new stake in Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM) in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 18,027 shares of the company’s stock, valued at approximately $27,000. Point72 Asia Singapore Pte. Ltd. owned approximately 0.05% of Reneo Pharmaceuticals as of its most recent filing with the SEC.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Pale Fire Capital SE raised its holdings in Reneo Pharmaceuticals by 102.7% during the fourth quarter. Pale Fire Capital SE now owns 30,100 shares of the company’s stock valued at $48,000 after buying an additional 15,249 shares in the last quarter. Marquette Asset Management LLC acquired a new position in shares of Reneo Pharmaceuticals during the 1st quarter valued at about $122,000. Vestal Point Capital LP bought a new position in shares of Reneo Pharmaceuticals in the 4th quarter valued at approximately $640,000. Finally, Highbridge Capital Management LLC lifted its holdings in Reneo Pharmaceuticals by 6.5% in the 2nd quarter. Highbridge Capital Management LLC now owns 2,915,376 shares of the company’s stock worth $4,402,000 after purchasing an additional 178,806 shares during the last quarter. Institutional investors and hedge funds own 90.98% of the company’s stock.

Insider Activity

In other Reneo Pharmaceuticals news, major shareholder Braden Michael Leonard acquired 55,300 shares of the business’s stock in a transaction that occurred on Tuesday, September 17th. The stock was acquired at an average price of $1.36 per share, with a total value of $75,208.00. Following the transaction, the insider now owns 3,358,243 shares of the company’s stock, valued at $4,567,210.48. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Over the last ninety days, insiders have acquired 256,239 shares of company stock valued at $355,105. 17.90% of the stock is owned by insiders.

Reneo Pharmaceuticals Stock Up 0.6 %

Shares of Reneo Pharmaceuticals stock opened at $1.71 on Wednesday. Reneo Pharmaceuticals, Inc. has a 12-month low of $0.98 and a 12-month high of $9.21. The stock has a 50 day moving average price of $1.48 and a two-hundred day moving average price of $1.59.

Reneo Pharmaceuticals (NASDAQ:RPHM) last posted its earnings results on Tuesday, August 13th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.01. On average, analysts predict that Reneo Pharmaceuticals, Inc. will post -0.65 EPS for the current fiscal year.

About Reneo Pharmaceuticals

Reneo Pharmaceuticals, Inc, a clinical-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases. The company's lead product candidate is REN001, a potent and selective agonist of the peroxisome proliferator-activated receptor delta that is in clinical development for genetic mitochondrial diseases comprising primary mitochondrial myopathies and long-chain fatty acid oxidation disorders.